@article {McGroder2021.03.17.21253834, author = {Claire F. McGroder and David Zhang and Mohammad A. Choudhury and Mary M. Salvatore and Belinda M. D{\textquoteright}Souza and Eric A. Hoffman and Ying Wei and Matthew R. Baldwin and Christine Kim Garcia}, title = {Pulmonary Fibrosis after COVID-19 is Associated with Severity of Illness and Blood Leukocyte Telomere Length}, elocation-id = {2021.03.17.21253834}, year = {2021}, doi = {10.1101/2021.03.17.21253834}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The risk factors for development of fibrotic interstitial lung abnormalities (ILA) after severe COVID-19 are incompletely described and the extent to which CT findings correlate with symptoms and physical function after hospitalization remain unclear. At 4 months after hospitalization, fibrotic ILA was more common in those who underwent mechanical ventilation (72\%) than in those who did not (20\%). We demonstrate that severity of initial illness, duration of mechanical ventilation, lactate dehydrogenase on admission, and leukocyte telomere length are independent risk factors for fibrotic ILA. These fibrotic changes correlate with lung function, cough and measures of frailty, but not with dyspnea.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the NIH (R01HL103676, R01HL093096 to CKG; T32HL105323 to CM; UL1TR001873 to MRB) and the Department of Defense (PR202907 to CKG and MRB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Columbia University Irving Medical Center (CUIMC) Institutional Review Board study protocol number is AAAR1916.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Raw data were generated at Columbia University Medical Center. Derived data supporting the findings of this study are available from the corresponding author [CG] on request.}, URL = {https://www.medrxiv.org/content/early/2021/03/20/2021.03.17.21253834}, eprint = {https://www.medrxiv.org/content/early/2021/03/20/2021.03.17.21253834.full.pdf}, journal = {medRxiv} }